Lenalidomide Zentiva (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4CRBN E3 ubiquitin ligase complex, changing the complex’s substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, leading to reduced proliferation, increased apoptosis of malignant cells, inhibition of angiogenesis, and modulation of the immune response.

The prescribed dose of Lenalidomide Zentiva is set by the treating physician based on the specific indication, disease stage, patient weight, renal function, and prior therapy. Dosing regimens differ between multiple myeloma, MDS with del(5q), and mantle cell lymphoma, and the clinician tailors the schedule to balance efficacy with safety.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of a high risk of fetal harm and teratogenicity. Women of childbearing potential must use effective contraception before, during, and after treatment. Breastfeeding is not recommended, as the drug can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenalidomide Zentiva. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug (IMiD) class, but lenalidomide is more potent, has a different toxicity profile, and generally causes fewer peripheral neuropathy events. Lenalidomide also offers greater efficacy in myelodysplastic syndromes with del(5q) and is often preferred when a stronger anti‑angiogenic and immunomodulatory effect is needed.

Lenalidomide Zentiva tablets should be stored at room temperature, below 25 °C, in the original blister pack or bottle. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Lenalidomide Zentiva is taken orally, usually with a glass of water. The tablet can be swallowed whole and may be taken with or without food, depending on the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Serious risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Rare but critical events include secondary primary malignancies, severe skin reactions like Stevens‑Johnson syndrome, and hepatic failure. Prompt medical attention is required if any of these occur.

Lenalidomide Zentiva should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with severe renal impairment unless dose‑adjusted by a physician. It is also contraindicated in patients receiving live vaccines or in those with uncontrolled thromboembolic risk without appropriate prophylaxis.